Pengrong Yan

Memorial Sloan Kettering Cancer Center — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

24h-index2.1kcitations61works3.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Heat shock proteins research(14), Lung Cancer Research Studies(9), Computational Drug Discovery Methods(8), T-cell and Retrovirus Studies(8), Cancer Immunotherapy and Biomarkers(7)

Publications61 total

Author response: Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2
2024Open Access
Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2
eLife·2024· 3 citedOpen Access
Phosphorylation-driven epichaperome assembly is a regulator of cellular adaptability and proliferation
Nature Communications·2024· 22 citedOpen Access
Neutrophil extracellular trap related risk score exhibits crucial prognostic value in skin cutaneous melanoma, associating with distinct immune characteristics
Skin Research and Technology·2024· 2 citedOpen Access
Phosphorylation-Driven Epichaperome Assembly: A Critical Regulator of Cellular Adaptability and Proliferation
2024· 1 citedOpen Access
Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2
2024· 2 citedOpen Access
Author Response: Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2
2024Open Access
Reviewer #2 (Public Review): Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2
2024Open Access
Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2
eLife·2023· 2 citedOpen Access
NanoPDLIM2 enhanced efficacy of PD-1 blockade and chemotherapy in mouse lung cancers
2023· 1 citedOpen Access
Reviewer #3 (Public Review): NanoPDLIM2 enhanced efficacy of PD-1 blockade and chemotherapy in mouse lung cancers
2023Open Access
Reviewer #1 (Public Review): NanoPDLIM2 enhanced efficacy of PD-1 blockade and chemotherapy in mouse lung cancers
2023Open Access
Reviewer #2 (Public Review): NanoPDLIM2 enhanced efficacy of PD-1 blockade and chemotherapy in mouse lung cancers
2023Open Access
Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2
2023· 1 citedOpen Access
Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation
Nature Communications·2023· 40 citedOpen Access
How aberrant N-glycosylation can alter protein functionality and ligand binding: An atomistic view
Structure·2023· 33 citedOpen Access
Data from DNA Methylation–Dependent Repression of PDZ-LIM Domain–Containing Protein 2 in Colon Cancer and Its Role as a Potential Therapeutic Target
2023Open Access
Data from DNA Methylation–Dependent Repression of PDZ-LIM Domain–Containing Protein 2 in Colon Cancer and Its Role as a Potential Therapeutic Target
2023Open Access
Supplementary Figures 1-4 from DNA Methylation–Dependent Repression of PDZ-LIM Domain–Containing Protein 2 in Colon Cancer and Its Role as a Potential Therapeutic Target
2023Open Access
Supplementary Figures 1-4 from DNA Methylation–Dependent Repression of PDZ-LIM Domain–Containing Protein 2 in Colon Cancer and Its Role as a Potential Therapeutic Target
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Gabriela Chiosis(24), Gutian Xiao(17), Zhaoxia Qu(17), Anna Rodina(15), Tony Taldone(15), Hediye Erdjument‐Bromage(10), Palak Panchal(9), Suhasini Joshi(9), Sahil Sharma(9), Tai Wang(8), Mary L. Alpaugh(8), Adriana Corben(8), Chenghua Yang(8), Chander Singh Digwal(8), Mónica L. Guzmán(7), Pallav D. Patel(7), Jing Fu(7), Thomas A. Neubert(7), Stephen D. Ginsberg(7), Steven D. Shapiro(7)